12:00 AM
Jul 06, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Hexvix regulatory update

PhotoCure submitted an NDA to FDA for Hexvix to detect papillary bladder cancer using fluorescence cystoscopy. In 2006, the company received a not...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >